Ellevest Inc. Has $48,000 Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Ellevest Inc. boosted its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 279.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,595 shares of the company’s stock after purchasing an additional 18,851 shares during the quarter. Ellevest Inc.’s holdings in Ginkgo Bioworks were worth $48,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. ARK Investment Management LLC grew its holdings in Ginkgo Bioworks by 3.0% in the second quarter. ARK Investment Management LLC now owns 169,749,527 shares of the company’s stock worth $315,734,000 after purchasing an additional 4,992,542 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Ginkgo Bioworks by 19.2% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 50,787,547 shares of the company’s stock valued at $94,465,000 after buying an additional 8,190,952 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Ginkgo Bioworks by 7.7% during the first quarter. BlackRock Inc. now owns 50,664,080 shares of the company’s stock valued at $67,383,000 after buying an additional 3,608,124 shares during the last quarter. Nikko Asset Management Americas Inc. grew its holdings in shares of Ginkgo Bioworks by 13.5% during the first quarter. Nikko Asset Management Americas Inc. now owns 42,596,595 shares of the company’s stock valued at $55,802,000 after buying an additional 5,082,277 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Ginkgo Bioworks by 5.8% during the first quarter. State Street Corp now owns 14,707,508 shares of the company’s stock valued at $19,560,000 after buying an additional 800,982 shares during the last quarter. 56.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Ginkgo Bioworks news, insider Reshma P. Shetty sold 37,650 shares of Ginkgo Bioworks stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $1.50, for a total value of $56,475.00. Following the sale, the insider now owns 12,600,454 shares of the company’s stock, valued at $18,900,681. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Ginkgo Bioworks news, Director Christian O. Henry sold 4,499 shares of Ginkgo Bioworks stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $4,499.00, for a total value of $20,241,001.00. Following the sale, the director now owns 1,238,878 shares of the company’s stock, valued at $5,573,712,122. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Reshma P. Shetty sold 37,650 shares of Ginkgo Bioworks stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $1.50, for a total transaction of $56,475.00. Following the completion of the sale, the insider now directly owns 12,600,454 shares in the company, valued at approximately $18,900,681. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,148,952 shares of company stock worth $22,360,554. 15.05% of the stock is owned by insiders.

Ginkgo Bioworks Stock Performance

Ginkgo Bioworks stock opened at $1.45 on Wednesday. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $1.12 and a fifty-two week high of $2.76. The firm’s 50-day simple moving average is $1.68 and its 200 day simple moving average is $1.76.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on DNA shares. BTIG Research cut shares of Ginkgo Bioworks from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. Raymond James cut shares of Ginkgo Bioworks from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $3.50 to $2.50 in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $3.19.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.